Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Jeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
Alejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
European Journal of Clinical Pharmacology
|
August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
Mace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Gynecologic Oncology
|
December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study
Mace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
International Journal of Nanomedicine
|
February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasis
Jose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
The Oncologist
|
January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancer
Richard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Jeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
Alejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
European Journal of Clinical Pharmacology
|
August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
Mace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Gynecologic Oncology
|
December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study
Mace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
International Journal of Nanomedicine
|
February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasis
Jose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
The Oncologist
|
January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancer
Richard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Page
of 6